LEAP-004 study: > 4 year follow up

Prof Jean-François Baurain, Cliniques Universitaires Saint-Luc, Brussels gave a concise summary of the LEAP-004 study. With over four years of follow-up, lenvatinib in combination with pembrolizumab continued to demonstrate antitumor activity in patients with advanced melanoma who progressed on anti–PD-(L)1 therapy.